Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry
Adriana Pleșa(Hospices Civils de Lyon), Xavier Thomas(Hôpital Lyon Sud), Marie Balsat(Hôpital Claude Huriez), Joris Gutrin(Hospices Civils de Lyon), Mohamed Elhamri(Hôpital Edouard Herriot), Christophe Roumier(Université de Lille), Fiorenza Barraco(Hôpital Lyon Sud), Marie‐Virginie Larcher, Isabelle Tigaud(Inserm), Gaëlle Fossard(Hospices Civils de Lyon), Pierre Sujobert(Université Claude Bernard Lyon 1), Octavia Cadassou(Hospices Civils de Lyon), Sandrine Hayette(Hôpital Claude Huriez), Amandine Baudouin, Sophie Ducastelle(Hôpital Lyon Sud), Hélène Labussière(Hôpital Lyon Sud), Maël Heiblig(Université Claude Bernard Lyon 1)
Cited by 7
Related Papers
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
|Journal of Clinical Oncology|2003|606
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
|Journal of Clinical Oncology|2009|562
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547